WT1 and acute lymphoblastic leukemia: In the entire cohort of BCP-ALL, patients in group A (with WT1 overexpression) had inferior 5-year OS and EFS rates compared to those in group B (OS: 80.3 ± 4.7% vs. 90.5 ± 1.4%, P = 0.008; EFS: 79.8 ± 2.4% vs. 86.9 ± 2.1%, P = 0.021).